Sign up to save your podcasts
Or
Share How to Build and Sell a Biotech in 2024
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Build and Sell a Biotech in 2024
With a combined deal value of $29bn under their belts this year, four CEOs reflect on what they’ve learned from their successes – and failures. Roberto Bellini (who sold BELLUS Health), Mark McKenna (Prometheus), Bill Meury (Karuna Therapeutics) and Dan O’Connor (Ambrx Biopharma) also consider the current market for biopharma M&A and what buyers are seeking today.
View all episodes
By RBC Capital Markets
4.9
1818 ratings
With a combined deal value of $29bn under their belts this year, four CEOs reflect on what they’ve learned from their successes – and failures. Roberto Bellini (who sold BELLUS Health), Mark McKenna (Prometheus), Bill Meury (Karuna Therapeutics) and Dan O’Connor (Ambrx Biopharma) also consider the current market for biopharma M&A and what buyers are seeking today.
More shows like Strategic Alternatives
View all
Exchanges
983 Listeners
Invest Like the Best with Patrick O'Shaughnessy
2,346 Listeners
Pod Save America
87,983 Listeners
The Daily
113,122 Listeners
Pod Save the World
24,822 Listeners
Front Burner
453 Listeners
The Intelligence from The Economist
2,549 Listeners
The Compound and Friends
2,155 Listeners
Thoughts on the Market
1,314 Listeners
Strict Scrutiny
5,832 Listeners
Morning Brew Daily
3,051 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,260 Listeners
Hard Fork
5,544 Listeners
The Ezra Klein Show
16,315 Listeners